Scarica l'app Stockscreener
40.31
5.36%
2.05
Dopo l'orario di chiusura:
40.30
-0.01
-0.02%
Precedente Chiudi:
$38.26
Aprire:
$39.31
Volume 24 ore:
2.82M
Relative Volume:
2.39
Capitalizzazione di mercato:
$8.27B
Reddito:
$1.97B
Utile/perdita netta:
$92.93M
Rapporto P/E:
99.14
EPS:
0.4066
Flusso di cassa netto:
$459.60M
1 W Prestazione:
+0.40%
1M Prestazione:
+1.41%
6M Prestazione:
-9.53%
1 anno Prestazione:
-4.81%
Intervallo 1D:
$38.68
$41.30
Intervallo di 1 settimana:
$38.13
$41.44
Portata 52W:
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Nome
Qiagen Nv
Settore
Industria
Telefono
-
Indirizzo
-
Confronta QGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
40.31 | 8.27B | 1.97B | 92.93M | 459.60M | 0.4066 |
|
TMO
Thermo Fisher Scientific Inc
|
437.87 | 165.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
180.62 | 130.05B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
378.99 | 31.91B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
103.59 | 29.55B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.01 | 27.28B | 15.41B | 1.37B | 2.11B | 7.50 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-10-17 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-06-27 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-07 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-09-12 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-23 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-10-14 | Iniziato | Redburn | Buy |
| 2021-07-14 | Downgrade | Kepler | Buy → Hold |
| 2021-06-03 | Iniziato | Goldman | Neutral |
| 2020-10-06 | Ripresa | BofA Securities | Buy |
| 2020-09-28 | Aggiornamento | Kepler | Hold → Buy |
| 2020-08-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-08-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2020-08-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Downgrade | Berenberg | Buy → Hold |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-12-26 | Ripresa | BofA/Merrill | Underperform |
| 2019-11-15 | Iniziato | Stifel | Hold |
| 2019-11-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Aggiornamento | Kepler | Reduce → Hold |
| 2019-10-17 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Downgrade | Kepler | Hold → Reduce |
| 2019-10-08 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Qiagen Nv Borsa (QGEN) Ultime notizie
Qiagen stock gains after guidance raise (QGEN:NYSE) - Seeking Alpha
Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance - Benzinga
Qiagen: Q1 beat; profitability guidance upgraded - MarketScreener
QIAGEN NV : Deutsche Bank maintains a Buy rating - MarketScreener
QIAGEN NV : UBS gives a Neutral rating - MarketScreener
Qiagen the only DAX stock to risehigher profit forecast helps - MarketScreener
QIAGEN NV : Jefferies gives a Buy rating - MarketScreener
QIAGEN Smashes Q1 Targets: 7% Growth Powers Confident 2025 Outlook Boost - Stock Titan
QIAGEN Crushes Q1 Targets: Key Products Surge, EPS Guidance Raised to $2.35 - Stock Titan
Qiagen Says Q1 Adjusted EPS $0.55 - MarketScreener
Redburn Atlantic Downgrades Qiagen N.V. (BIT:1QGEN) - Nasdaq
Qiagen Announces Voting Rights Update with Bank of America - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Redburn cuts QIAGEN stock rating, lowers price target to EUR41 - Investing.com
Redburn cuts QIAGEN stock rating, lowers price target to EUR41 By Investing.com - Investing.com South Africa
Redburn-Atlantic Downgrades QIAGEN NV (QIA:GR) (QGEN) to Neutral - StreetInsider
Lab Automation Market Top PlayersF. Hoffmann-La Roche, Qiagen - openPR.com
Personalized Medicine Market Growth Trends 2025-2033: Transition to Customized Medical Care, Developments in Bioinformatics and Genomics, Growing Prevalence of Chronic Diseases - GlobeNewswire Inc.
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts - BioSpace
Qiagen introduces QIAprep Plasmodium kit to strengthen malaria research efforts - BioSpectrum Asia
Revolutionary Malaria Test Kit: QIAGEN's New Solution Detects 5 Species with Single-Parasite Sensitivity - Stock Titan
QIAGEN N.V. Files 2024 Annual Report with SEC - TipRanks
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results - DutchNews.nl
PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] - TradingView
QIAGEN Releases Full 2024 Annual Report: Access Complete Financial Data and Analysis - Stock Titan
Qiagen revenue 2012-2024 - Statista
Are Qiagen N.V.'s (NYSE:QGEN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance
QIAGEN NV : Jefferies reiterates its Buy rating - Marketscreener.com
Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 81% - simplywall.st
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label - Business Wire
Qiagen Manager Pledges Shares in Securities Lending Transaction - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
QGEN Stock Might Rise Following Partnership With Genomics England - MSN
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now? - Yahoo Finance
Digital Genome Market to Witness Remarkable Growth with QIAGEN, GenomeMe Inc., NanoString Technologies - openPR
The past three-year earnings decline for Qiagen (NYSE:QGEN) likely explains shareholders long-term losses - Yahoo Finance
Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
FDA clears Qiagen’s QIAstat-Dx Gastrointestinal Panel 2 Mini B - Medical Device Network
Qiagen at TD Cowen Conference: Strategic Growth Plans Unveiled - Investing.com
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday -March 06, 2025 at 09:14 am EST - Marketscreener.com
QIAGEN Gets US FDA Clearance for Second QIAstat-Dx Mini Gastrointestinal Panel -March 06, 2025 at 04:04 am EST - MarketScreener
How QIAGEN's Latest FDA Win Strengthens Its $4.6B Diagnostic Empire - Stock Titan
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio - Silicon Canals
Market is not liking Qiagen's (NYSE:QGEN) earnings decline as stock retreats 4.7% this week - Simply Wall St
Analyzing Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN) - Defense World
QIAGEN Announces Managerial Transactions Involving Performance Stock Units - TipRanks
QIAGEN Announces Managerial Stock Transaction - TipRanks
Qiagen Announces Managerial Stock Unit Grant - TipRanks
Qiagen Announces Managerial Stock Transactions - TipRanks
QIAGEN Announces Manager’s Transaction with Restricted Stock Units Grant - TipRanks
Qiagen N.V. (QGEN): Among the Cash-Rich Mid Cap Stocks to Buy Now - MSN
Qiagen Nv Azioni (QGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):